Table 1.
Pathway | Ovarian event | PCD type | Upstream regulators | Downstream effectors | Effect on ovarian cells | References |
---|---|---|---|---|---|---|
PI3K/AKT | PGC depletion | Apoptosis | KITLG |
Upregulation of BCL-2, BCL-XL, MCL-1 Inactivation of BIM, BAX, BAD, and FOXO3 |
Pro-survival | [72, 77–80] |
Follicular atresia | Apoptosis | FSH, IGF, EGF, bFGF |
Upregulation of NFκB, cFLIPL, BCL-2, MDM2, and XIAP Inactivation of caspase-8, BIM, BAX, BAD, FOXO1, and FOXO3 |
Pro-survival | [77, 141–144, 150, 157–170, 173–177] | |
Autophagy | FSH | Downregulation of MAP1LC3-II, BECN1, ATG7, and ATG12 | Pro-survival | [188, 191] | ||
Luteolysis | Apoptosis | PGF2α |
Inhibition of AKT Upregulation of BAX |
Pro-apoptotic | [247] | |
PLC/PKC | Follicular atresia | Apoptosis | FSH | Stabilization of cFLIPS | Pro-survival | [143] |
Luteolysis | Apoptosis | PGF2α | Activation of NFAT | Pro-apoptotic | [231, 242, 243] | |
Ca2+/AMPK | Luteolysis | Autophagy | PGF2α |
Activation of BECN1 Upregulation of MAP1LC3-II |
Pro-autophagic | [286] |
MEK/ERK | PGC depletion | Apoptosis | KITLG | Activation of RPS6KA1, MYC, STAT1/3 | Pro-survival | [72, 77] |
Follicular atresia | Apoptosis | FSH through β-arrestin | Activation of RPS6KA1, MYC, STAT1/3 | Pro-survival | [150, 152] | |
Luteolysis | Apoptosis | LH/hCG through β-arrestin | Activation of RPS6KA1, MYC | Pro-survival | [255, 261] | |
Autophagy | PGF2α | Upregulation of MAP1LC3-II | Pro-autophagic | [288] | ||
cAMP/PKA | Follicular atresia | Apoptosis | FSH |
Phosphorylation of CREB, ERK1/2, AKT, GSK3B, β-catenin, FOXO1, p38 MAPK Downregulation of BIM |
Pro-survival | [153–155] |
Luteolysis | Apoptosis | LH/hCG |
Progesterone synthesis stimulation Activation of CREB, GSK3B, and β-catenin Upregulation of LHCGR, BCL-2, MCL-1, survivin, STAR, and PGE2α Downregulation of BAX and CD95/Fas |
Pro-survival | [156, 256–258, 262, 263, 265–269, 277] | |
PGE2α | Upregulation of LHCGR, BCL-2, STAR | Pro-survival | [273, 277] | |||
Autophagy | LH/hCG | Downregulation of MAP1LC3-II | Pro-survival | [286] | ||
Estrogen signaling | Luteolysis | Apoptosis | Progesterone |
Downregulation of CD95/Fas Upregulation of BCL-2 |
Pro-survival | [270–273] |
HIF1α | Follicular atresia | Autophagy | Hypoxic stress, FSH | Upregulation of PINK1, Parkin, and BNIP3 | Pro-survival | [197–201] |
Luteolysis | Autophagy | PGF2α | Upregulation of BNIP3 | Pro-autophagic | [287] | |
JAK/STAT | PGC depletion | Apoptosis | LIF | Upregulation of BCL-2, BCL-XL, MCL-1 | Pro-survival | [74–76] |
Follicular atresia | Apoptosis | IFNγ | Upregulation of CD95/Fas | Pro-apoptotic | [125–128] | |
Luteolysis | Apoptosis | PGF2α |
Activation of STAT3 Upregulation of SOCS3 |
Not defined/pro-apoptotic | [247] | |
IFNγ | Upregulation of CD95/Fas | Pro-apoptotic | [224, 232] | |||
CHK2/p53/p63 | PGC depletion | Apoptosis | Lack of growth factors, nutrient starvation, stress |
Activation of p53/TAp63 Upregulation of NOXA, BBC3, and BAX |
Pro-apoptotic | [35, 63–65, 84, 85] |
Death receptor/FADD/caspase-8 | PGC depletion | Apoptosis | TNFα | Activation of BAK, BAX, and caspase-3 | Pro-apoptotic | [87] |
TRAIL | Activation of BAK, BAX, and caspase-3 | Pro-apoptotic | [88] | |||
Follicular atresia | Apoptosis | FasL | Activation of BAK, BAX, and caspase-3 | Pro-apoptotic | [117–126] | |
TNFα |
Activation of BAK, BAX, and caspase-3 Downregulation of BCL-2 |
Pro-apoptotic | [126, 131–133] | |||
TRAIL/DR4/5 receptors | Activation of BAK, BAX, and caspase-3 | Pro-apoptotic | [88, 134–136] | |||
Luteolysis | Apoptosis | FasL | Activation of BAK, BAX, and caspase-3 | Pro-apoptotic | [123, 125, 228, 229] | |
TNFα |
Activation of BAK, BAX, and caspase-3 Upregulation of CD95/Fas |
Pro-apoptotic | [224, 226, 229, 231, 232] | |||
NFκB-RelA | Follicular atresia | Autophagy | FSH |
Activation of JNK Upregulation of MAP1LC3-II |
Pro-autophagic, pro-survival | [193] |
Luteolysis | Apoptosis | IFNγ | Upregulation of CD95/Fas | Pro-apoptotic | [224, 232, 235, 236] | |
TNFα | Upregulation of CD95/Fas | Pro-apoptotic | [224, 232, 235, 236] | |||
RIPK1/RIPK3 | Follicular atresia | Apoptosis | SIRT1 | Activation of caspase-3 | Pro-apoptotic | [210] |
Necroptosis | AChE-R-derived peptide | Activation of MLKL | Pro-necroptotic | [207–209] | ||
Luteolysis | Apoptosis | PGF2α | Activation of RIPK3 and caspase-8 | Pro-apoptotic | [292] | |
Necroptosis | AChE-R-derived peptide | Activation of MLKL | Pro-necroptotic | [207] | ||
Ceramide | Activation of MLKL | Pro-necroptotic | [289] | |||
Iron turnover | PGC depletion | Ferroptosis | Transferrin, PCBP2 | SLC7A11 | Not defined | [110, 111] |
NF2/YAP | Follicular atresia | Ferroptosis | BNC1 inactivation |
Downregulation of GPX4 Upregulation of NOX1, COX2, TFRC and ACSL4 |
Pro-ferroptotic | [212] |
xc− system | Follicular atresia | Ferroptosis | circRHBG-miR-515-5p | Cystine metabolism | Pro-ferroptotic | [214] |
Pathways are not determined up to date | PGC depletion | Apoptosis | Starvation at birth | Upregulation of BAX | Pro-apoptotic | [103] |
Autophagy | Starvation at birth | Upregulation of MAP1LC3-II and LAMP1 | Pro-autophagic, contradictory effects | [103, 105] | ||
Follicular atresia | Apoptosis | Oxidative stress |
Upregulation of BIM and caspase-3 Activation of caspase-3 |
Pro-apoptotic | [195] | |
Autophagy | Oxidative stress |
Activation of JNK Upregulation of BECN1, ATG5, ATG7, and MAP1LC3-II |
Pro-autophagic, pro-ADCD | [194, 195] | ||
Luteolysis | Apoptosis | PGF2α |
Upregulation of FasL, CD95/Fas, BAX, IFNγ, and TNFα Activation of caspase-3 |
Pro-apoptotic | [221, 244, 245, 248] | |
TNFα | Stimulation of PGF2α secretion | Pro-apoptotic | [246] | |||
Autophagy | PGF2α | Upregulation of MAP1LC3-II | Pro-autophagic, pro-survival | [248] |